President Trump is trying, yet again, to climb out of the political mire into which he has sunk over the Jeffrey Epstein scandal. On Wednesday, Trump sought to pin the blame on unnamed Republicans … ...

Akebia Therapeutics (AKBA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?

Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multi-phase approach ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for relapsed/refractory multiple myeloma.

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...